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their disease stage. The methodological framework here presented uses 
prevalent cohort survival data to reconstruct stage-specific survival rates, as 
they would be if obtained from an incident cohort. METHODS: This approach 
assumes proportional hazards and, under certain caveats, can be generalized to 
non-proportional hazards. Through a piece-wise back calculation approach 
recent survival data are fed and integrated into the model to calculate survival at 
earlier stages of the disease, this allows the reconstruction of the survival 
probability as a function of the time elapsed from the onset of illness. This 
method is then generalized to allow comparison between ‘placebo’ and 
‘treatment’ prevalent-cohorts. RESULTS: The method is very general and can be 
applied to a variety of cases. As an example, the only published data on an 
untreated tuberculosis prevalent cohort is used to infer the actual mortality rates 
of untreated tuberculosis through the course of the illness. The results show that 
mortality is highest within the first two years of illness, declining dramatically 
immediately after and increasing again to intermediate rates after one year, 
suggesting population heterogeneity with respect to the risk of dying from 
tuberculosis-related illness. In general, if sufficient data on a ‘placebo’ and on a 
‘treatment’ cohorts is available, this method can be used to infer the potential 
stage-specific effectiveness of a treatments. CONCLUSIONS: Under specific 
modeling assumptions, incident-cohort survival and treatment effect can be 
inferred from prevalent-cohort studies.  
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OBJECTIVES: Post-menopausal women are under-diagnosed in claims data even 
though they exhibit symptoms. Probabilistic linkage was conducted between 
claims data and The University of Michigan Women’s Registry data to control for 
post-menopausal symptoms as risk factors in the analysis. METHODS: Women 
with a menopause diagnosis who used estrogen only hormone therapy (HT) were 
selected from the registry data. A separate group of patients age 45 or older who 
were prescribed estrogen only HT was selected from a large U.S. claims database. 
Logistic regression was conducted to calculate the propensity score for each 
patient, controlling for women’s health-related comorbidities in each population. 
Patients with the closest propensity score from each group were matched, and 
the menopause symptoms of Registry patients were added to the claims records 
of the corresponding matched patients in the claims data. This linkage process 
was repeated 250 times, and the mean and 95% confidence interval (CI) of health 
care costs during the follow-up period were calculated. RESULTS: Among 2771 
women, 16% (N=443) were diagnosed as post-menopausal. Of this subset, 83 
patients prescribed estrogen only HT were selected. After probabilistic linking 
with the 20,020 selected women from the claims database, 80 patients from each 
population were matched. The average cost of patients with at least one 
symptom was much higher compared to patients without symptoms ($13,570 
[95% CI: $13,459-$13,680] vs. $3,391 [95% CI: $3,345-$3,436], p-value<0.001). Cost 
differences were mainly from inpatient ($1,997 [95% CI: $1,925-$2,070], p-
value<0.001 vs. $247 [95% CI: $239-$254, p-value<0.001), physician visit ($967 [95% 
CI: $961-$974], p-value<0.001 vs. $248 [95% CI: $246- $251], p-value<0.001), and 
pharmacy costs ($3,676 [95% CI: $3,648-$3,704], p-value<0.001 vs. $903 [95% CI: 
$890-$916], p-value<0.001). CONCLUSIONS: The study suggests that post-
menopausal symptoms are important risk factors to control when assessing 
health care costs in claims data. Probabilistic linkage can bridge the gap between 
claims and registry data information.  
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OBJECTIVES: To evaluate the equivalence of electronic and paper versions of the 
Psoriasis Symptom Inventory (PSI) and examine measurement properties of the 
electronic version. METHODS: In a prospective, randomized, cross-over, non-
interventional study in adult subjects (age ≥ 18 years) with plaque psoriasis 
conducted over a 15-day period , subjects were randomized to two groups, each 
completing either the paper or electronic PSI daily for 7 consecutive days 
followed by the alternate version. The disease specific Dermatology Life Quality 
Index [DLQI]) and the generic SF36v2 were also administered for evaluation of 
construct validity. Equivalence was assessed by the intraclass correlation 
coefficient (ICC) between both modes. Differences in scores between the 
administration modes were also tested using paired Student’s t-test. 
Measurement properties included internal consistency reliability, test-retest 
reliability, and construct validity. Convergent and discriminant validity were 
evaluated using pre-identified logical relationships between similar or distally 
related concepts. RESULTS: Eighty subjects (74% [59/80] moderate-to-severe 
psoriasis; 26% [21/80] mild psoriasis receiving systemic treatment) were enrolled 
from 8 sites in the United States. Seventeen (21%) subjects experienced a change 
in sPGA and were excluded from analyses. The paper and electronic modes of 
the PSI were highly concordant for both total scores (ICC = 0.969) and individual 
item scores (ICC range 0.934 to 0.965). Findings remained consistent (ICC values 
were all >0.91) irrespective of order of completion for the paper and electronic 
versions. All mean score differences were non-significant (p > 0.05) except for 
“flaking”; however, based on its reliability, validity, and clinical relevance, the 
item was retained. Minimum values for reliability (>0.70) and validity 
(convergent, r ≥ 0.30) were exceeded for the electronic PSI. CONCLUSIONS: 
Equivalence between paper and electronic versions of the PSI and the two 
modes’ comparable measurement properties indicated successful migration 
from paper to electronic format of the PSI.  
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OBJECTIVES: No standardized methods exist to measure outcomes related to 
Acute Bacterial Skin and Skin Structure Infections (ABSSSI). The purpose of this 
literature review was to identify clinical measurement concepts for other skin 
abnormalities that could be applied to ABSSSI. The results were used to inform 
the development of a standardized measurement tool and/or a novel Clinician 
Reported Outcome (ClinRO) for ABSSSI. METHODS: To identify relevant 
abstracts/articles for inclusion a search was conducted in OVID. MEDLINE (1946-
present) and EMBASE (1988-2012) were searched using terms related to ClinRO, 
measurement tools and devices, diagnostic tools, and skin 
diseases/abnormalities. RESULTS: The search identified 428 abstracts. 381 were 
excluded based on pre-specified criteria. The remaining 47 full-text articles were 
scrutinized for eligibility, resulting in 30 that met the inclusion criteria. No 
ABSSSI-specific ClinROs or measurement tools were identified in the literature. 
Several clinical concepts related to the measurement and evaluation of skin 
abnormalities were found e.g. Psoriasis Area and Severity Index; Vancouver Scar 
Scale; Pressure Ulcer Scale for Healing; Pressure Sore Status Tool and the Bates-
Jensen Wound Assessment Tool. Disease-severity instruments were also 
identified e.g. Severity Scoring of Atopic Dermatitis scale; Eczema Area and 
Severity Index; Investigators Global Assessment; Six Area, Six Sign Atopic 
Dermatitis severity index. Devices used to evaluate characteristics of skin 
abnormalities range from simple and inexpensive (ruler), to advanced and 
expensive (laser based tools). No single device was found that measures the full 
spectrum of a skin infection. CONCLUSIONS: There is a paucity of ABSSSI-
specific clinical endpoints/ClinRO measures in the existing literature. This 
review highlights the need to develop a standardized ClinRO instrument to 
assess clinical measurement concepts in ABSSSI. Robust scales, tools, and 
devices that measure or evaluate skin diseases and infections were identified. 
These could be considered when developing a standardized ABSSSI 
measurement tool and/or a novel ClinRO.  
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OBJECTIVES: The EuroQol Group is evaluating the use of discrete choice 
experiments (DCEs) in valuing health states from the 5-level EQ-5D (EQ-5D-5L). 
Notably, a discrete choice (DC) model yields a latent utility that is ordinal and 
unbounded, whereas health utilities must have interval properties and be 
anchored at 0 (representing death) and 1 (representing full health). Latent 
utilities must therefore be transformed to health utilities. This pilot study 
investigated the feasibility of performing such a transformation. METHODS: 545 
respondents from Canada and 403 respondents from the UK each completed a 
series of DC and TTO tasks. Generalised linear mixed models were used to derive 
latent utilities. Linear regression models incorporating logarithmic and 
polynomial terms, as well as non-parametric LOESS and spline models were 
assessed as candidate functions for transforming the latent utilities onto the 
health utilities. RESULTS: There was a high correlation between health utilities 
measured through TTO tasks and latent utilities derived from modelling of DC 
data (Spearman rho of 0.79 in Canada and 0.86 in the UK). All transforming 
functions explained the between-state variation in health utilities, and, upon 
cross-validation, had minimal bias and small mean squared errors. Whilst the 
transformation functions derived through linear regression had the desirable 
feature of being monotone, the LOESS transform in Canada and the spline 
transform in the UK lacked monotonicity. CONCLUSIONS: This pilot study 
suggests that transforming latent utilities to health utilities is feasible, and 
provides preliminary evidence that linear regression involving polynomial and 
logarithmic terms may be more desirable than non-parametric spline or LOESS 
functions.  
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OBJECTIVES: Photo-based questionnaires have been used to evaluate aesthetic 
treatment outcomes such as wrinkle reduction and eyelash growth. The 
objective of this study was to develop a photonumeric guide of scar severity 
intended for use by both clinicians and patients to measure scar treatment 
